Dr. Reddy's Laboratories introduces Colchicine tablets in US market

Anthony Fernandes
/ Categories: Trending, DSIJ News
Dr. Reddy's Laboratories introduces Colchicine tablets in US market

On Friday, Dr. Reddy's Laboratories and its subsidiaries informed the bourses, after-market hours that the company launched Colchicine tablets USP in the US markets. The drug is available in 0.6 mg tablets in bottle count sizes of 30s and 100s.

Colchicine tablets USP is the therapeutic equivalent generic version of Colcrys (colchicine) tablets, 0.6 mg, which are approved by United States Food and Drug Administration (USFDA). According to MAT data from IMS Health and Quintiles (IQVIA) for the most recent twelve-month ending in March 2020, the Colcrys brand and generic market had US sales of about US$ 491 million.

Dr Reddy's Laboratories is an integrated pharmaceutical company offering a portfolio of products and services comprising APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations, and spanning across major markets such as India, USA, Russia and CIS countries, and Europe.

On Friday, the stock of the company closed at Rs 4,008.95, down by 1.15 per cent or Rs 46.65 per share. The 52-week high is Rs 4,189.35 and the 52-week low is Rs 2,352 on BSE.

Rate this article:
5.0

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

IPO Analysis29-Mar, 2024

Expert Speak29-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR